HLS Therapeutics (TSE:HLS) Hits New 12-Month Low at $3.25

HLS Therapeutics Inc. (TSE:HLS)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$3.25 and last traded at C$3.50, with a volume of 812 shares trading hands. The stock had previously closed at C$3.35.

Analyst Ratings Changes

A number of research firms have recently weighed in on HLS. Raymond James lowered their target price on HLS Therapeutics from C$5.00 to C$4.00 in a research note on Friday, May 10th. Stifel Nicolaus dropped their target price on shares of HLS Therapeutics from C$4.15 to C$3.75 in a report on Friday, May 10th.

HLS Therapeutics Price Performance

The firm’s 50-day moving average is C$3.92 and its 200-day moving average is C$4.06. The company has a market cap of C$109.74 million, a PE ratio of -2.86 and a beta of 1.14. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 99.86.

HLS Therapeutics (TSE:HLS) last released its quarterly earnings data on Thursday, May 9th. The company reported C($0.26) earnings per share for the quarter, missing the consensus estimate of C($0.25) by C($0.01). HLS Therapeutics had a negative net margin of 45.81% and a negative return on equity of 26.78%. The company had revenue of C$16.82 million for the quarter, compared to analysts’ expectations of C$19.61 million. On average, equities analysts anticipate that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.